Company Overview of Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor that intends to enter Phase III clinical trials for immune thrombocytopenic purpura and a Phase II clinical trial for immunoglobulin A nephropathy; R348, a topical janus kinase/SYK inhibitor in Phase II clinical trials for the treatment of keratoconjunctivitis sicca or chronic dry eye; R118, an adenosine monophosphate-activated protein kinase activator that intends to enter Phase I cl...
1180 Veterans Boulevard
South San Francisco, CA 94080
Founded in 1996
Key Executives for Rigel Pharmaceuticals, Inc.
Chief Executive Officer
Total Annual Compensation: $551.7K
Total Annual Compensation: $559.6K
Chief Financial Officer
Total Annual Compensation: $441.3K
Chief Medical Officer and Executive Vice President
Total Annual Compensation: $521.3K
Compensation as of Fiscal Year 2013.
Rigel Pharmaceuticals, Inc. Key Developments
Rigel Pharmaceuticals, Inc.(NasdaqGS:RIGL) dropped from NASDAQ Biotechnology Index
Dec 21 14
Rigel Pharmaceuticals, Inc. will be removed from the NASDAQ Biotechnology Index.
Rigel Pharmaceuticals, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 09:00 AM
Dec 3 14
Rigel Pharmaceuticals, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 09:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Raul R. Rodriguez, Chief Executive Officer, President and Director.
Rigel Pharmaceuticals, Inc. Announces Executive Changes
Nov 24 14
Rigel Pharmaceuticals, Inc. announced James M. Gower is retiring from the board of directors and from his positions as chairman and chief executive officer, and Raul Rodriguez, most recently serving as the company's president and chief operating officer, will assume the position of chief executive officer and join the board of directors. Gary Lyons, a member of Rigel's Board of Directors since 2005, will become chairman. Mr. Gower is expected to remain an employee until the end of the year and, thereafter will be a consultant to the company providing advice on strategy, business development and other matters. Mr. Gower joined Rigel as president and chief executive officer in January 1997. He was named chairman of the board in October 2001. Under his guidance, Rigel grew from a small startup to a significant developer of small molecule therapeutics for a range of immune and metabolic disorders. Mr. Gower is a widely respected and well known leader in the biotech community, having previously served as president and chief executive officer of Tularik, Inc. (later acquired by Amgen), and as senior vice president at Genentech Inc. prior to its merger with Roche. Mr. Rodriguez joined Rigel in April 2000 as vice president of business development. He was named executive vice president and chief operating officer in June 2004, and has been president and chief operating officer since May 2010. In addition to overseeing the day-to-day operations of Rigel, Mr. Rodriguez has been pivotal in developing relationships with biopharmaceutical industry leaders and observers, speaking on behalf of the company and the industry at major events. Prior to joining Rigel, Mr. Rodriguez held senior management, business development and operations roles at Ontogeny, Inc. and Scios, Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|